1. Home
  2. PD vs MESO Comparison

PD vs MESO Comparison

Compare PD & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PD
  • MESO
  • Stock Information
  • Founded
  • PD 2009
  • MESO 2004
  • Country
  • PD United States
  • MESO Australia
  • Employees
  • PD N/A
  • MESO N/A
  • Industry
  • PD Computer Software: Prepackaged Software
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PD Technology
  • MESO Health Care
  • Exchange
  • PD Nasdaq
  • MESO Nasdaq
  • Market Cap
  • PD 1.5B
  • MESO 1.3B
  • IPO Year
  • PD 2019
  • MESO N/A
  • Fundamental
  • Price
  • PD $16.41
  • MESO $15.75
  • Analyst Decision
  • PD Hold
  • MESO Buy
  • Analyst Count
  • PD 9
  • MESO 3
  • Target Price
  • PD $18.33
  • MESO $18.00
  • AVG Volume (30 Days)
  • PD 2.5M
  • MESO 234.2K
  • Earning Date
  • PD 09-03-2025
  • MESO 08-28-2025
  • Dividend Yield
  • PD N/A
  • MESO N/A
  • EPS Growth
  • PD N/A
  • MESO N/A
  • EPS
  • PD N/A
  • MESO N/A
  • Revenue
  • PD $483,608,000.00
  • MESO $17,198,000.00
  • Revenue This Year
  • PD $9.16
  • MESO $288.50
  • Revenue Next Year
  • PD $6.79
  • MESO $173.73
  • P/E Ratio
  • PD N/A
  • MESO N/A
  • Revenue Growth
  • PD 8.20
  • MESO 191.39
  • 52 Week Low
  • PD $13.70
  • MESO $6.09
  • 52 Week High
  • PD $21.98
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • PD 52.34
  • MESO 56.32
  • Support Level
  • PD $15.74
  • MESO $14.97
  • Resistance Level
  • PD $16.68
  • MESO $15.66
  • Average True Range (ATR)
  • PD 0.79
  • MESO 0.49
  • MACD
  • PD -0.07
  • MESO 0.08
  • Stochastic Oscillator
  • PD 69.55
  • MESO 92.51

About PD PagerDuty Inc.

PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: